Navigation Links
Emerging staph strains found to be increasingly deadly and deceptive

A study of how the immune system reacts to strains of antibiotic-resistant Staphylococcus aureus bacteria--emerging strains that sicken otherwise healthy people, or so-called "community-acquired" infections--has shown for the first time that these strains are more deadly and better at evading human immune defenses than more common S. aureus strains that originate in hospitals and other health-care settings.

In a paper released today online in The Journal of Immunology, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, describe how community-acquired S. aureus strains that survive treatment with the methicillin family of antibiotics can evade immune defenses. Infections from community-acquired methicillin-resistant S. aureus, or MRSA, are difficult to treat and are increasing nationally at an alarming rate, say experts.

Scientists at NIAID's Rocky Mountain Laboratories (RML) in Hamilton, MT, and colleagues examined the ability of MRSA strains to cause disease in mice and avoid destruction by human white blood cells called neutrophils. Neutrophils, which typically ingest and then kill harmful bacteria, make up about 60 percent of all white blood cells and are the first line of defense against bacteria. Scientists know that community-acquired strains differ from hospital strains, but they don't know why the community strains cause more serious infection in otherwise healthy people.

The work also identified specific S. aureus genes that potentially control the bacterium's escape from neutrophils. Among thousands of S. aureus genes analyzed in the five different strains used in the study, the scientists identified a large group of genes whose role in helping spread infection is unknown. RML's Frank DeLeo, Ph.D., the investigator who directed the study, and colleagues plan to determine if some of the unknown genes help promote disease. If they can learn which genes control t he ability of S. aureus to evade and destroy neutrophils, their work could lead to new medical treatments.

"Each day physicians around the world are stymied by the inability to effectively treat patients suffering from severe S. aureus infections," says NIAID Director Anthony S. Fauci, M.D. "There is a critical need to develop new treatments against late-stage disease caused by antibiotic-resistant strains, and this promising work offers several new approaches."

According to the Centers for Disease Control and Prevention, "recent reports of 'community-acquired' MRSA infections raise concern ?If MRSA becomes the most common form of Staphylococcus aureus in a community, it will make treatment of common infections much more difficult." The April 7, 2005, issue of The New England Journal of Medicine refers in an editorial to "?an epidemic of MRSA in the community."

S. aureus strains acquired in health-care settings can be challenging to resolve because of antibiotic resistance, which limits the choices for treatment. But the situation can become more serious with the newer community-acquired strains, says Dr. DeLeo. "We do not know why cases of community-acquired MRSA infections are increasing, let alone how they flourish," he says. But scientists do know the community strains can cause more severe forms of disease.

Mild S. aureus infections such as impetigo, which typically forms small blisters on the faces of children, or cellulitis, an inflammation of skin or muscle tissue, can easily be treated and usually resolve in a matter of days. But S. aureus disease also can be much more severe and difficult to treat, affecting vital organs and leading to toxins poisoning the blood and infection overwhelming the heart. One of the most severe types of disease is necrotizing pneumonia, where bacteria destroy lung tissue.

"The reason that some mild infections become severe or fatal is not well understood, but virulence is often associated with certain strains," says Jovanka Voyich, Ph.D., of RML, the study's lead author. To cause human disease, bacterial pathogens must avoid being killed by neutrophils. "These results," says Dr. Voyich, "suggest that community-acquired MRSA causes disease in healthy people in part because it has enhanced ability to circumvent killing by neutrophils."


'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Related biology news :

1. Ticks, flukes, and genomics: Emerging pathogens revealed
2. Substance protects resilient staph bacteria
3. Study indicates dramatic rise in antibiotic-resistant community-acquired staph infections
4. Less virulent strains of avian influenza can infect humans
5. Study outlines genetic differences between potential pandemic influenza strains
6. Human behavior changes the number of strains of infectious diseases
7. Experimental vaccine protects lab animals against several strains of H5N1
8. Complexity constrains evolution of human brain genes
9. New test for most virulent HPV strains under study
10. New component of the brakes on nerve regeneration found
11. Strongest proof yet found for prion hypothesis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology: